Clinical Trial: First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07637981) titled 'First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss' on April 30.

Brief Summary: Phase 2a: Multiple Ascending Dose (MAD) in male and female patients with hearing loss:

The study will be conducted according to a randomised, placebo-controlled, double-blind design. A total of 24 patients, otherwise healthy, aged up to 75 years old, with mild to moderate hearing loss will be included. Two cohorts of 12 male or female patients (no ratio is required) will receive two different flat doses (low dose and high dose) ofDX243 or placebo for 29 days using SC administration. I...